Aravive Inc
F:VE11
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Bank of Hawaii Corp
NYSE:BOH
|
US |
|
Changsha Broad Homes Industrial Group Co Ltd
HKEX:2163
|
CN |
|
AC Energy Corp
OTC:ACPIF
|
PH |
|
D
|
Dream Residential Real Estate Investment Trust
TSX:DRR.U
|
CA |
|
Domo Inc
NASDAQ:DOMO
|
US |
|
Shanghai Yaohua Pilkington Glass Group Co Ltd
SSE:600819
|
CN |
|
FS Development Investment Holdings
SZSE:300071
|
CN |
|
Hewlett Packard Enterprise Co
NYSE:HPE
|
US |
|
Mayfield Group Holdings Ltd
ASX:MYG
|
AU |
|
Peninsula Land Ltd
NSE:PENINLAND
|
IN |
|
Hanwha Solutions Corp
KRX:009830
|
KR |
Aravive Inc
Research & Development
Aravive Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Aravive Inc
F:VE11
|
Research & Development
-$53.4m
|
CAGR 3-Years
-58%
|
CAGR 5-Years
-51%
|
CAGR 10-Years
-14%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Research & Development
-$9.1B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-8%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Research & Development
-$5.7B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-7%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Research & Development
-$7.2B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-6%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Research & Development
-$3.9B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-15%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Research & Development
-$5.2B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-12%
|
|
Aravive Inc
Glance View
Aravive, Inc. operates as a clinical stage biotechnology company. The company is headquartered in Houston, Texas and currently employs 23 full-time employees. The company went IPO on 2014-03-20. The firm is focused on developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. Its lead product candidate, AVB-500, is an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway associated with tumor cell growth, tumor metastasis, resistance to treatment, and decreased survival. The firm is evaluating AVB-500 in a registrational Phase III trial in platinum resistant ovarian cancer, a Phase Ib/2 trial in second line plus, clear cell renal cell carcinoma (ccRCC), and a Phase Ib/2 trial in first-line treatment of pancreatic adenocarcinoma. The Company’s lead candidate, Aravive-S6 (AVB-S6)-500, is a GAS6 binding protein and AXL decoy receptor. The company is a Fc-fusion protein designed to block the activation of the growth arrest-specific 6 (GAS6)-AXL signaling pathway by intercepting the binding of GAS6 to its receptor AXL.
See Also
What is Aravive Inc's Research & Development?
Research & Development
-53.4m
USD
Based on the financial report for Sep 30, 2023, Aravive Inc's Research & Development amounts to -53.4m USD.
What is Aravive Inc's Research & Development growth rate?
Research & Development CAGR 10Y
-14%
Over the last year, the Research & Development growth was 13%. The average annual Research & Development growth rates for Aravive Inc have been -58% over the past three years , -51% over the past five years , and -14% over the past ten years .
